About GASTER Technology — A European MedTech Company | GASTER control
About GASTER Technology — European MedTech for Satiety Science
GASTER Technology Limited is a Malta-based medical device company developing GASTER control®, a CE-marked external abdominal compression device for the complementary support of satiety regulation in obesity care.
Who we are
GASTER Technology Limited is a medical device company incorporated under Maltese law, with operations spanning Malta, France, and other European markets. Our work focuses on a specific physiological dimension of food intake regulation: the mechanosensorial pathway of satiety — one of the complementary pathways that contribute to the integrated satiety signal, alongside hormonal, cognitive, and emotional inputs.
The company develops, manufactures (through a qualified European supply chain), and commercialises GASTER control®, a Class I medical device under EU MDR 2017/745, designed to be used within structured medical care pathways and under medical supervision. The device is positioned as a complement to existing therapeutic approaches — GLP-1 receptor agonists, bariatric surgery, dietetic and behavioral support — and is not intended as a substitute for any of them.
Our institutional posture is exploratory. Mechanosensorial signaling remains under-characterised in current obesity research compared to the hormonal pathway. Our work aims to contribute to its clinical understanding through structured observational data, scientific exchange, and ongoing engagement with the European bariatric and metabolic community — including the European Association for the Study of Obesity (EASO) and the European Chapter of IFSO. Our positioning aligns with the multimodal frameworks promoted by these societies, which recognise complementary approaches alongside pharmacological and surgical pathways.
From Malta to European deployment
GASTER Technology Limited was established in Valletta, Malta, a jurisdiction we chose for its position at the crossroads of European MedTech innovation and the Mediterranean clinical landscape. Malta provides an English-speaking corporate environment within the European Union, with regulatory alignment to the European Medicines Agency framework and access to the EUDAMED database for medical device traceability.
From this Maltese foundation, our first clinical and commercial deployment took place in France, where the device is distributed through the Lipoline network of orthotics specialists. France was selected as our launch market for two reasons: a dense and structured bariatric and metabolic ecosystem (over a dozen Centres Spécialisés Obésité, the SOFFCO.MM scientific society, the AFERO research network), and an established regulatory framework for orthotics-class medical devices.
Our trajectory now extends across Europe. Commercial development is actively underway across additional European markets, with a structured rollout planned for the United Kingdom and the DACH region (Germany, Austria, Switzerland) in 2027, alongside ongoing exploration of OEM partnerships with European medical device distributors.
CE marking obtained
MDR EU 2017/745 conformity, Class I, December 2025.
France deployment & registry launch
Lipoline distribution, GC-REG-01 observational registry, SOFFCO.MM 2026.
UK & DACH expansion
United Kingdom, Germany, Austria, Switzerland. First OEM partnerships.
What we do
Our activity is structured around three interconnected pillars.
The device — GASTER control®
GASTER control® is an inflatable external abdominal belt, designed to apply controlled, adjustable, and reproducible mechanical compression in the epigastric region. It is a Class I medical device under EU MDR 2017/745 (EMDN code Y.06.03.99, abdominal binder), available in three sizes, intended for use within medical care pathways under healthcare professional supervision.
The research — observational registry GC-REG-01
Our clinical research is structured around a multicentre observational registry, GC-REG-01, coordinated by Dr Marius Nedelcu (Clinique Bouchard, Marseille) and operated on Obeli HDS, a French health-data-hosting platform compliant with European data protection standards. An initial exploratory study (n = 11) was presented at SOFFCO.MM 2026 in Marseille.
The registry currently spans multiple French centres, with planned European expansion to additional investigators. Its initial enrollment target is set at up to 200 patients, with the possibility of extension as the registry develops. The scientific committee continues to welcome new investigators contributing to the documentation of mechanosensorial signaling within integrated obesity care.
The scientific engagement
Our scientific committee gathers bariatric surgeons, endocrinologists, and clinicians active in the obesity care field. The committee oversees the registry methodology, contributes to the scientific positioning of the device, and engages with the broader European bariatric and metabolic community through congresses, publications, and structured dialogue with peer societies.
Key figures
Leadership
The company is led by Alexandra Vorbauer, Chief Executive Officer and Director of Publication, overseeing corporate strategy, regulatory affairs, and scientific engagement. Day-to-day operations are conducted in coordination with the scientific committee, manufacturing partners, and the commercial network.
The scientific committee brings together bariatric surgeons, endocrinologists, and clinicians from leading European hospitals and clinics. It is independent in its evaluations and decisions regarding clinical methodology, and is coordinated for the GC-REG-01 registry by Dr Marius Nedelcu, bariatric surgeon at Clinique Bouchard (Marseille, France).
Corporate identity
GASTER Technology Limited
- Legal form
- Private limited company (Ltd) — Maltese law
- Registered office
- 5/1 Merchants Street
Valletta VLT 1171
Malta — European Union - Trade register
-
C 84832(Malta Business Registry) - EUDAMED SRN
MT-MF-000047377- Regulatory framework
- EU MDR 2017/745 — Class I medical device
- Quality system
- Aligned with ISO 13485:2016 requirements
- Manufacturing
- ISO 13485:2016 certified supply chain
- Risk management
- EN ISO 14971:2019 applied
- Device tradename
- GASTER control® (commercial) — LIPOLINE (regulatory)
- CE notice reference
-
LLGC20251201(issued 1 December 2025) - CEO & Director of Publication
- Alexandra Vorbauer
Get in touch
For commercial enquiries, distribution partnerships, clinical collaboration, regulatory questions, or press requests.
Contact details Legal noticeGASTER control® is not an alternative to GLP-1 therapies or to bariatric surgery. It is approached as a complementary mechanosensorial adjunct within integrated care pathways. The level of clinical evidence currently available remains preliminary; the ongoing observational registry GC-REG-01 aims to expand it.
For institutional inquiries, please refer to our Legal Notice and Contact Details.